# MARCH BIOSCIENCES INC: A Phase 2 multi-center trial of CD5 CAR T-cell therapy in patients with T-cell lymphoma

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | MARCH BIOSCIENCES INC |
| Location | HOUSTON, TX |
| Project | A Phase 2 multi-center trial of CD5 CAR T-cell therapy in patients with T-cell lymphoma |
| Project number | 5R44CA302357-02 |
| Mechanism | R44 |
| Institute | National Cancer Institute |
| Award | $1,124,607 |
| Awarded | 2026-08-31 |
| Project period | 2025-07-01 to 2027-06-30 |
| UEI | TB1TRLB85UY7 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11370276). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.